IP

Ionis Pharmaceuticals, Inc.

Every trial this sponsor leads in the registry, and everything it has published.

122All trials
Recruiting8
Recruited9
Not yet recruiting1
By invitation1
Completed92
Stopped10
Other1

19 active · 16% of this sponsor’s registry footprint

Genetic & Rare Disease4 trials
Neurology3 trials
Immunology & Inflammation2 trials
Metabolic/Endocrine/Nutrition2 trials
Cardiovascular1 trial

Not shown above: 7 trials whose condition matched no therapy area.

Trials by phase

Phase 140
Phase 252
Phase 326
Phase 41
Unphased3

Pipeline by phase · 12 drugs in active development

Phase 3 · 6 drugs

Olezarsen4 trials · 1 recruitingest. Mar 2027
Donidalorsen2 trials · 1 recruitingest. Dec 2026
Eplontersen2 trialsest. Aug 2029
Obudanersen Sodium (ION582)2 trials · 1 recruitingest. Aug 2027
Ulefnersen (ION363)1 trial
zilganersen1 trial

Phase 2 · 1 drug

ION7751 trial · 1 recruitingest. Sept 2027

Phase 1 · 5 drugs

Erisonersen Sodium (ION717)1 trialest. Apr 2027
ION3371 trial · 1 recruitingest. Dec 2030
ION3561 trial · 1 recruitingest. Jun 2028
ION4401 trial · 1 recruitingest. Sept 2027
ION4641 trial · 1 recruitingest. Sept 2027

Active trials only, code names and brands merged. 92 completed trials are in the counts above but their drugs are not folded into this pipeline.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon